Poliovirus type 2 antigen (formaldehyde inactivated)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Poliovirus type 2 antigen (formaldehyde inactivated)
- Accession Number
- DB10796
- Description
Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Inactivated poliomyelitis vaccine (D.C.O.) type 2 MEF1
- Inactivated poliovirus type II
- poliovirus vaccine inactivated, type 2 (MEF-1)
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 23JE9KDF4R
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Acellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B 1 4 Completed Prevention Acellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus 1 4 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B 1 4 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus 1 4 Completed Prevention Drug Therapy, Combination / Fever, Chemically Induced / Infants / Vaccines, Pneumococcal 1 4 Completed Prevention Flu caused by Influenza 1 4 Completed Prevention Pertussis 1 4 Completed Prevention Poliomyelitis 4 4 Completed Prevention Streptococcal Infections 1 4 Completed Prevention Vaccines, Pneumococcal 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular 2 Lf/0.5mL Injection, suspension Intramuscular 5 ug/0.5mL Injection, solution Intramuscular 8 mcg/0.5ml Suspension Intramuscular 2 IU/0.5ml Injection, suspension Intramuscular 8 mcg/0.5ml Injection, suspension Intramuscular 20 UI Injection, solution Intramuscular 20 IU Injection, suspension Intramuscular 25 mcg/0.5ml Injection, suspension Intramuscular; Subcutaneous 40 U Suspension Subcutaneous Injection, suspension Intramuscular; Subcutaneous 40 [D'ag'U]/0.5mL Injection Injection Intramuscular Injection, powder, for suspension Intramuscular 25 mcg Injection, powder, for suspension Intramuscular 30 UI Suspension Intramuscular 30 UI Injection, powder, for suspension Intramuscular 10 mcg Injection, powder, for suspension Intramuscular 25 mcg/0.5ml Injection, powder, for suspension Intramuscular 8 μg Injection, suspension Intramuscular 40 [D'ag'U]/0.5mL Injection, suspension Intramuscular Injection, powder, for suspension Intramuscular 30 IU/0.5ml Injection Intramuscular 30 IU Injection, suspension Intramuscular 2 IU Injection, suspension Intramuscular 20 IU/0.5ml Injection, suspension Intramuscular 2 IU/0.5ml Injection, suspension Intramuscular 2 UI Injection, suspension Intramuscular 30 UI Injection, suspension Intramuscular 30 IU Injection, suspension Intramuscular 30 IU/0.5mL Injection, solution Intramuscular 40 D angtigen units - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 20:04 / Updated on June 12, 2020 16:53